Showing results (931-940 of 1,024) with videos related to

Sort By:
Pageof 103
Blood|March 2, 2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expressionVikas A Gupta, Benjamin G Barwick, Shannon M Matulis, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2021
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignanciesKatharine A Collier, Hugo Valencia, Herbert Newton, et al.
Laryngoscope Investigative Otolaryngology|October 20, 2021
Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomasD Bradley Welling, Katharine A Collier, Sarah S Burns, et al.
Blood|April 13, 2013
MicroRNAs activate natural killer cells through Toll-like receptor signalingShun He, Jianhong Chu, Lai-Chu Wu, et al.
Molecular Cancer Therapeutics|January 27, 2016
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple MyelomaAndrew Stiff, Enrico Caserta, Douglas W Sborov, et al.
Journal of Medical Genetics|November 9, 2013
Different mutations in PDE4D associated with developmental disorders with mirror phenotypesAnna Lindstrand, Giedre Grigelioniene, Daniel Nilsson, et al.
Life (Basel, Switzerland)|June 2, 2021
How to Improve the Management of Acute Ischemic Stroke by Modern Technologies, Artificial Intelligence, and New Treatment MethodsKamil Zeleňák, Antonín Krajina, Lukas Meyer, et al.
Frontiers in Immunology|October 8, 2025
CD8<sup>+</sup> T-NK cell crosstalk establishes preemptive immunosurveillance to eliminate antigen-escape tumorsRoman V Uzhachenko, Salvador González Ochoa, Thanigaivelan Kanagasabai, et al.
Leukemia|September 16, 2018
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myelomaP G Richardson, C C Hofmeister, N S Raje, et al.
Leukemia|June 24, 2017
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myelomaP G Richardson, C C Hofmeister, N S Raje, et al.
Pageof 103